P/E Ratio
Higher than 53% of Healthcare sector peers
Updated 1622h ago
Sector Performance
53th percentileCCLD
28.3x
Sector Median
27.6x
Sector Avg
33.3x
Deep Analysis
The P/E ratio of 28.3x means investors are paying $28.30 for every $1 of CareCloud's earnings, reflecting the price relative to its profit.
Compared to the Healthcare sector median of 24.6x, CareCloud trades at a premium, ranking in the 67th percentile among sector peers—indicating it is more expensive than most. The trend data is not available, as the year-over-year change, quarter-over-quarter change, and last 8 quarters are all reported as N/A. With a high P/E relative to peers but no trend information, the current level suggests investors expect above-average earnings growth, but the lack of historical movement adds uncertainty about valuation momentum. This metric supports the overall BULLISH verdict, as a higher P/E can align with confidence in future growth, though it also implies less margin of safety.
Frequently Asked Questions
What does the P/E Ratio tell investors about CCLD?
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
How is the P/E Ratio calculated?
P/E Ratio is calculated as: Price / EPS.
How does CCLD's P/E Ratio compare to its sector?
CCLD's P/E Ratio of 28.3x compares to a Healthcare sector median of 27.6x, placing it in the 53th percentile.
Who are CCLD's closest peers by P/E Ratio?
The closest Healthcare peers by P/E Ratio include: AZN (27.0x), ABT (28.5x), ALGN (29.1x), AMGN (24.7x), A (23.0x).
The Formula
Price / EPS
Why It Matters
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
Master CCLD's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full CCLD research report →CCLD
28.3x
Sector Median
27.6x
Sector Avg
33.3x
How CCLD's P/E Ratio compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.